Phase I/Ii Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients With High Risk (HR) Multiple Myeloma (MM)

Biology of Blood and Marrow Transplantation - Netherlands
doi 10.1016/j.bbmt.2012.11.111
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

CD34-selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed, High-Risk Multiple Myeloma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Extramedullary vs Medullary Relapse After Autologous or Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Multiple Myeloma (MM) and Its Correlation to Clinical Outcome

Bone Marrow Transplantation
TransplantationHematology
2004English

Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With Fludarabine/Melphalan in Patients With Myelofibrosis

Biology of Blood and Marrow Transplantation
TransplantationHematology
2012English

Acute Cognitive Impairment in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant

Cancer
Cancer ResearchOncology
2013English

Post-Transplant Lymphoproliferative Disorder in Patients With Lymphoma After Allogeneic Hematopoietic Stem Cell Transplantation

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Lenalidomide Induced Graft-Versus-Host Disease in a Patient With Relapsed Multiple Myeloma Three and a Half Years After Allogeneic Hematopoietic Stem Cell Transplantation

Journal of Hematopoietic Cell Transplantation
2013English

Phase II Trial to Investigate Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy